KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inovio Pharmaceuticals (INO) Interest Expenses (2019 - 2024)

Inovio Pharmaceuticals' Interest Expenses history spans 6 years, with the latest figure at $177833.0 for Q1 2024.

  • For Q1 2024, Interest Expenses fell 43.27% year-over-year to $177833.0; the TTM value through Dec 2024 reached $177833.0, down 85.46%, while the annual FY2024 figure was $177833.0, 85.46% down from the prior year.
  • Interest Expenses for Q1 2024 was $177833.0 at Inovio Pharmaceuticals, down from $282325.0 in the prior quarter.
  • Across five years, Interest Expenses topped out at $2.8 million in Q2 2020 and bottomed at $177833.0 in Q1 2024.
  • The 5-year median for Interest Expenses is $313488.0 (2022), against an average of $781968.9.
  • The largest annual shift saw Interest Expenses soared 327.24% in 2020 before it plummeted 83.6% in 2021.
  • A 5-year view of Interest Expenses shows it stood at $1.1 million in 2020, then plummeted by 55.03% to $480313.0 in 2021, then crashed by 34.73% to $313488.0 in 2022, then decreased by 9.94% to $282325.0 in 2023, then tumbled by 37.01% to $177833.0 in 2024.
  • Per Business Quant, the three most recent readings for INO's Interest Expenses are $177833.0 (Q1 2024), $282325.0 (Q4 2023), and $313488.0 (Q3 2023).